Sarepta's Elevidys Gene Therapy Shows Lasting Benefits Three Years After Treatment for Duchenne Muscular Dystrophy

Sarepta Therapeutics reports positive three-year results for Elevidys gene therapy in Duchenne patients, showing 70% slowing of disease progression and sustained motor function improvements, boosting investor confidence.